Hamburg based PLS-Design GmbH receives BioChancePLUS funding
PLS-Design GmbH, Hamburg, has now found a practicable solution. With the support of the North German Life Science Agency Norgenta the company has successfully applied for funding from the German Federal Ministry for Education and Research for this project. The goal is a standardized diagnostic tool for reliably controlling the progress of allergen-desensitizing treatment. The new method will initially only be applied for insect venom allergies. After all, the new approach will help approximately 3 million affected patients with an improved therapy.
The research project funded with 370,000 EUR is effected in a cooperation of the Hamburg based biotech company with the University of Hamburg, the Technical University of Munich as well as the University of Anhalt in Bernburg. PLS-Design will produce for the first time a number of recombinant human IgE-antibodies that are similar to those in patients' blood. These specific antibodies will be used as components of artificial patient sera for a general standardization of allergy tests.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous